CC
Casdin Capital Portfolio holdings
AUM
$1.1B
This Quarter Return
+42.47%
1 Year Return
+24.98%
3 Year Return
+152.8%
5 Year Return
+110.01%
10 Year Return
–
AUM
$354M
AUM Growth
+$354M
(+42%)
Cap. Flow
+$47.4M
Cap. Flow
% of AUM
13.38%
Top 10 Holdings %
Top 10 Hldgs %
61.1%
Holding
34
New
–
Increased
14
Reduced
4
Closed
5
Top Buys
| 1 |
Alnylam Pharmaceuticals
ALNY
|
$11.2M |
| 2 |
BLUE
bluebird bio
BLUE
|
$11M |
| 3 |
GNMK
GenMark Diagnostics, Inc
GNMK
|
$7.85M |
| 4 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
$7.07M |
| 5 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$5.12M |
Top Sells
| 1 |
EPZM
Epizyme, Inc
EPZM
|
$7.85M |
| 2 |
Gilead Sciences
GILD
|
$5.31M |
| 3 |
AMRS
Amyris Inc.
AMRS
|
$1.59M |
| 4 |
TSRO
TESARO, Inc.
TSRO
|
$1.23M |
| 5 |
Pacific Biosciences
PACB
|
$1.07M |
Sector Composition
| 1 | Healthcare | 85.27% |
| 2 | Materials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Ovid Therapeutics
OVID
$91M
| $1.78M | 0.5% | 207,500 -14,200 | -6% | -$122K |
|
27
Curis
CRIS
$20.9M
| – | – | -85,000 | Closed | -$161K |
|
|
28
Gilead Sciences
GILD
$140B
| – | – | -75,000 | Closed | -$5.31M |
|
29
Myriad Genetics
MYGN
$593M
| – | – | 0 | – | – |
|
|
30
Pacific Biosciences
PACB
$393M
| – | – | -300,000 | Closed | -$1.07M |
|
31
SPDR S&P Biotech ETF
XBI
$5.07B
| – | – | 0 | – | – |
|
|
MDRX
32
DELISTED
Veradigm Inc. Common Stock
MDRX
| – | – | 0 | – | – |
|
|
AMRS
33
DELISTED
Amyris Inc.
AMRS
| – | – | -500,000 | Closed | -$1.59M |
|
|
EPZM
34
DELISTED
Epizyme, Inc
EPZM
| – | – | -520,000 | Closed | -$7.85M |
|